European Cancer Congress 2015 Conference Insight.
Four key stories around the conferences key findings
30 September 2015
The European Cancer Congress (ECC 2015) is a biennial congress which combines the efforts of the most important European oncology professionals with the aim of improving the prevention, diagnosis, treatment and care of cancer patients.
Our analysts have put together a free white paper which allows you to take a look at four key outcomes from the meeting, allowing you to analyze them in more details and understand how these findings effect the oncology market.
- Late-breaking Phase II data reveal a promising future for atezolizumab (Roche) in NSCLC and bladder cancer. We think that despite competition from two PD-1s that are already approved (Keytruda and Opdivo), atezo has great potential in NSCLC. The data in bladder cancer suggest the drug will be a massive improvement for relapsed patients, and that the drug has potential to change the way is treated
- Late-breaking abstracts showcase continued development of PD-1/L1 checkpoint inhibitors across multiple cancer indications. Looking separately from atezolizumab (see below), we recap the key data from late-breaking abstracts of Opdivo (nivolumab; Bristol-Myers Squib), Keytruda (prembrolizumab; Merck & Co), and durvalumab (AstraZeneca) across a range of oncology indications.
- IMA901’s failure causes Immatics to shift focus. Immatics presented negative data for its cancer vaccine IMA901 in renal cell cancer. We look at what this means for the company, what it will do next.
- Data from LBAs of Opdivo and Cometriq studies in renal cell cancer suggest the two drugs are highly effective in second-line setting. We offer some insight as to what the data mean for the treatment landscape and which drug will fare better out of the two.
Fill out the form now to download your free white paper >>
If you’re already a Datamonitor Healthcare subscriber click here to view the full white paper >>
Posted in Oncology.